Some readers may have noticed that, late last week, the US Food and Drug Administration (FDA) approved a product known as lutetium Lu-177 dotatate or Lutathera for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Lu-177, lutetium-177 | 1 Comment »
Targeted nuclear medicine has shown some impressive outcomes in several small studies, mostly conducted in Germany. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Lu-177, lutetium-177, PSMA | 5 Comments »
We have been provided (by the developers) with additional information about a US-based, Phase II, clinical trial of a form of radiation therapy using the targeted agent lutetium-177 prostate-specific membrane antigen 617 (177Lu-PSMA-617) for treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: efficacy, Lu-177, mCRPC, PSMA, safety, Treatment, trial | 2 Comments »
One of the more important emerging forms of radiotherapy for metastatic castrate-resistant prostate cancer (mCRPC) is the radioactive element lutetium-177 (177Lu) chemically bonded to a ligand — an antibody or a small molecule that attaches to the prostate-specific membrane antigen (PSMA). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Lu-177, lutetium, radiation | 10 Comments »
Xofigo® (radium Ra-223 dichoride) has been a game-changer in the treatment of prostate cancer metastatic to bone. Not only does it provide significant pain palliation and reduce skeletal-related adverse events, but it slows down progression of the disease, increasing median survival by about 30 percent. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antigen, J591, Lu-177, lutetium, membrane, PSMA, radiation, surface, systemic | 19 Comments »
